AARD (AARD) reported R&D of $16.57M in Q1 2026.

How has AARD's R&D changed year-over-year?

AARD's R&D increased by 113.6% year-over-year, from $7.76M to $16.57M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

AARD AARD R&D

R&D at other companies

Relmada Therapeutics, Inc.RLMD

$8.09M-32.3%

Rhythm Pharmaceuticals, Inc.RYTM

$41.73M+12.9%

Aquestive Therapeutics, Inc.AQST

$4.2M-21.6%

Viking TherapeuticsVKTX

$150.15M+263%

ArvinasARVN

$60.3M-33.6%

Protagonist TherapeuticsPTGX

$46.74M+30.2%

Other financials

Income statement

See full

Revenue-—

Operating income-$22.5M-115%

Net income-$21.6M-132%

EPS (diluted)-$0.99-39.4%

Balance sheet

See full

Cash & equivalents$62.4M+136%

Total debt$336.0K-53.7%

Total equity$87.0M-42.3%

Total assets$98.6M-37.2%

Cash flow

See full

Operating cash flow-$18.9M-65.7%

CapEx--100%

Free cash flow-$16.8M-117%

Valuation

See full

Market cap$124.35M-58.6%

Enterprise value$62.25M-77.4%

Returns & leverage

See full

Return on equity-58.8%—

Debt / equity0×0.0×

Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AARD's R&D?: AARD (AARD) reported R&D of $16.57M in Q1 2026.
How has AARD's R&D changed year-over-year?: AARD's R&D increased by 113.6% year-over-year, from $7.76M to $16.57M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.